过敏性鼻炎治疗中地氯雷他定联合氮卓斯汀鼻喷剂的临床疗效及安全性分析  

Clinical Efficacy and Safety Analysis of Loratadine and Azelastine Nasal Spray in the treatment of Allergic Rhinitis

作　　者：朱丹[1] ZHU Dan(Fuxin Center Hospital,Liaoning Fuxing 123000,China)

机构地区：[1]辽宁省阜新市中心医院耳鼻咽喉科,辽宁阜新123000

出　　处：《河北医学》2018年第10期1727-1731,共5页Hebei Medicine

基　　金：辽宁省科技攻关计划项目;(编号:2015376158)

摘　　要：目的:研究过敏性鼻炎治疗中地氯雷他定联合氮卓斯汀鼻喷剂的临床疗效。方法:选取2015年2月至2017年1月就诊的共243例过敏性鼻炎患者作为研究对象,按随机数字表法将所有患者分为对照组(n=119例)和研究组(n=124例)。其中对照组患者采用氮卓斯汀鼻喷剂治疗,研究组患者采用地氯雷他定联合氮卓斯汀鼻喷剂,对比两组患者治疗前后IL-4、IL-6、IL-10等炎症因子水平,治疗前后VCAM-1、Ig E水平,治疗前后症状积分,治疗后临床疗效。结果:两组患者治疗前IL-4、IL-6和IL-10水平对比无统计学差异(P>0.05),研究组患者治疗后IL-4、IL-6和IL-10水平明显低于对照组,且两组患者治疗后明显低于各自治疗前,且均有统计学差异(P<0.05)。两组患者治疗前VCAM-1、Ig E水平对比无统计学差异(P>0.05),研究组患者治疗后VCAM-1、Ig E水平明显低于对照组,且两组患者治疗后明显低于各自治疗前,且均有统计学差异(P<0.05)。两组患者治疗前鼻痒、鼻塞、流涕、喷嚏等症状积分对比无统计学差异(P>0.05),研究组患者治疗后症状积分明显低于对照组,且两组患者治疗后明显低于各自治疗前,且均有统计学差异(P<0.05)。对照组患者总有效率为79.83%;研究组患者总有效率为96.77%,两组患者治疗总有效率对比有统计学差异(P<0.05)。对照组不良反应发生率为3.36%;研究组不良反应发生率为4.03%。不良反应在治疗结束后均自行缓解,未见肾脏、肝脏和心脏功能异常。结论:地氯雷他定联合氮卓斯汀鼻喷剂可减轻炎性反应,降低血清炎性因子,VCAM-1和Ig E水平,明显改善临床症状,提高治疗有效率,具有较好的治疗效果。Objective:To study the clinical efficacy of loratadine combined with azelastine nasal spray in the treatment of allergic rhinitis.Methods:243 patients with allergic rhinitis were enrolled in our hospital from February 2015 to January 2017.All patients were divided into control group(n=119)and study group(n=124)according to the random number table method.The patients in the control group were treated with azelastine nasal spray.The patients in the study group were treated with desloratadine and azelastine nasal spray,and the IL-4,IL-6,IL-10 and other inflammations were compared between the two groups before and after treatment.Factor levels,VCAM-1,IgE levels before and after treatment,symptom scores before and after treatment,and clinical efficacy after treatment.Results:There was no significant difference in the levels of IL-4,IL-6 and IL-10 before treatment between the two groups(P>0.05).The levels of IL-4,IL-6 and IL-10 were significantly lower in the study group than in the control group after treatment.Group,and two groups of patients after treatment significantly lower than their respective treatment,and were statistically significant(P<0.05).There was no significant difference in the levels of VCAM-1 and IgE between the two groups before treatment(P>0.05).The levels of VCAM-1 and IgE in the study group were significantly lower than those in the control group after treatment,and the two groups were significantly lower than the respective treatment after treatment.Before and with statistical differences(P<0.05).There was no significant difference in symptom scores before treatment between the two groups in terms of nasal itching,nasal congestion,runny nose,and sneezing(P>0.05).Symptom scores after treatment in the study group were significantly lower than those in the control group,and both groups were significantly lower after treatment.Before each treatment,there was a statistical difference(P<0.05).The total effective rate of the control group was 79.83%;the total effective rate of the study group was 96.7

关 键 词：过敏性鼻炎 地氯雷他定 氮卓斯汀鼻喷剂 

分 类 号：R765.21[医药卫生—耳鼻咽喉科]